Motti
Regular Member
- Joined
- Jun 1, 2017
- Messages
- 40
- Likes
- 57
The Case for Regionalism in a Post-Coronavirus World
COVID-19 has exposed the myopia and fragility underlying our worldwide supply chains. The first order of business, therefore, should be in ensuring the integrity of critical supply chains. Elected officials cannot play dice with basic necessities like food, medicines, clothing, public transportation, and the assorted nuts and bolts of daily societal functions. Supply chains should be shorter, less prone to exogenous risks, and must be dictated by long-term strategic imperatives rather than economics.
Take the global healthcare ecosystem, for instance. When COVID-19 struck, India — a traditional pharmaceutical powerhouse — was sourcing 70% of its active pharmaceutical ingredient (API) imports worth $2.4 billion from China. The figures appear worse for the US. According to a recent CFR blog, about 97% of all US antibiotics were sourced from China, on top of 80% of APIs used in local drug production. To make matters worse, both the US and India are engaged in a severe geopolitical logjam with China. Imagine the consequences of a full-scale trade war?
The Case for Regionalism in a Post-Coronavirus World
The lingering COVID-19 scourge continues to devastate the global economy. Initial fears of an impending supply chain shock, arising from shuttered Chinese factories, have instead led to a moth-eaten global economy where rising supply is met with depreciating demand and vice versa. To make...
russiancouncil.ru
COVID-19 has exposed the myopia and fragility underlying our worldwide supply chains. The first order of business, therefore, should be in ensuring the integrity of critical supply chains. Elected officials cannot play dice with basic necessities like food, medicines, clothing, public transportation, and the assorted nuts and bolts of daily societal functions. Supply chains should be shorter, less prone to exogenous risks, and must be dictated by long-term strategic imperatives rather than economics.
Take the global healthcare ecosystem, for instance. When COVID-19 struck, India — a traditional pharmaceutical powerhouse — was sourcing 70% of its active pharmaceutical ingredient (API) imports worth $2.4 billion from China. The figures appear worse for the US. According to a recent CFR blog, about 97% of all US antibiotics were sourced from China, on top of 80% of APIs used in local drug production. To make matters worse, both the US and India are engaged in a severe geopolitical logjam with China. Imagine the consequences of a full-scale trade war?